{"component": "definition", "props": {"groups": [{"size": 21, "snippet": "means a substance recognized by the body as being foreign; it results in the production of specific antibodies directed against it.", "samples": [{"hash": "iqJFL8yvUbG", "uri": "https://www.rld.state.nm.us/uploads/FileLinks/30148500fc59448da00d2ed9b2659868/April_2015_Approved_Minutes.pdf", "label": "www.rld.state.nm.us", "score": 7.7734427452, "published": false}, {"hash": "8aUToESpY21", "uri": "https://www.rld.nm.gov/uploads/FileLinks/30148500fc59448da00d2ed9b2659868/April_2015_Draft_Minutes_1.pdf", "label": "www.rld.nm.gov", "score": 7.7214236259, "published": false}, {"hash": "gdv912z0Vc5", "uri": "http://www.rld.state.nm.us/uploads/files/16_19_26%20POCT%20proposed.pdf", "label": "www.rld.state.nm.us", "score": 7.5181384087, "published": false}], "snippet_links": [{"key": "the-production", "type": "clause", "offset": [73, 87]}, {"key": "directed-against", "type": "definition", "offset": [111, 127]}], "hash": "91efe19bbbc8c909947187fe5958cd7f", "id": 1}, {"size": 12, "snippet": "means a substance that causes the immune system to produce antibodies against it.", "samples": [{"hash": "eQUr4gMRSxb", "uri": "https://rwandafda.gov.rw/wp-content/uploads/2024/02/Draft-Guidelines-for-registration-of-Human-Biological-Products.pdf", "label": "rwandafda.gov.rw", "score": 18.9352626801, "published": false}, {"hash": "3q9D4VlK9sU", "uri": "https://rwandafda.gov.rw/wp-content/uploads/2024/02/Draft-Guidelines-for-Registration-of-Biosimilar-Products.pdf", "label": "rwandafda.gov.rw", "score": 18.7751598358, "published": false}, {"hash": "ewc8yzJlgw3", "uri": "https://rwandafda.prod.risa.rw/index.php?eID=dumpFile&t=f&f=35942&token=c1e35798ae8b28465c252e9066ea758a0cfe6343", "label": "rwandafda.prod.risa.rw", "score": 15.3357772827, "published": false}], "snippet_links": [], "hash": "98d0719ad7c3f62a88374db5361f8954", "id": 2}, {"size": 10, "snippet": "means any protein (including any glyco- or lipo-protein), carbohydrate, compound or other composition, and any fragment, peptide or epitope thereof, that stimulates the production of antibodies.", "samples": [{"hash": "hXTJC12x2IS", "uri": "/contracts/hXTJC12x2IS#antigen", "label": "Research and Commercialization Agreement (Celldex Therapeutics Inc)", "score": 21.0, "published": true}, {"hash": "f4LQVNSzkPY", "uri": "/contracts/f4LQVNSzkPY#antigen", "label": "Research and Commercialization Agreement (Celldex Therapeutics Inc)", "score": 21.0, "published": true}, {"hash": "bQX6Ug6x2vD", "uri": "/contracts/bQX6Ug6x2vD#antigen", "label": "Research and Commercialization Agreement (Celldex Therapeutics Inc)", "score": 21.0, "published": true}], "snippet_links": [{"key": "the-production", "type": "clause", "offset": [165, 179]}], "hash": "34303d5302687c9112ea20d8f67905e5", "id": 3}, {"size": 9, "snippet": "means a molecule (i.e., protein, polypeptide, peptide, carbohydrate, glycoprotein, glycolipid and/or any combination of the foregoing that is, or is derived in whole or part from, a molecule associated with an infectious agent) that produces an Immune Response to such molecule in a human and/or animal recipient.", "samples": [{"hash": "ahNMEhvveyK", "uri": "/contracts/ahNMEhvveyK#antigen", "label": "Asset Contribution Agreement", "score": 31.3408622742, "published": true}, {"hash": "lVllZg8WphY", "uri": "/contracts/lVllZg8WphY#antigen", "label": "Series a Preferred Unit Purchase Agreement (Maxygen Inc)", "score": 22.3798770905, "published": true}, {"hash": "h450L2Tlbf6", "uri": "/contracts/h450L2Tlbf6#antigen", "label": "Asset Contribution Agreement (Maxygen Inc)", "score": 21.0, "published": true}], "snippet_links": [{"key": "the-foregoing", "type": "clause", "offset": [120, 133]}, {"key": "associated-with", "type": "definition", "offset": [191, 206]}, {"key": "infectious-agent", "type": "definition", "offset": [210, 226]}, {"key": "immune-response", "type": "definition", "offset": [245, 260]}], "hash": "7556a16f9aef3ba85ccaea98be610f6c", "id": 4}, {"size": 9, "snippet": "means (a) any protein (including any glyco- or lipo-protein), carbohydrate, compound or other composition that stimulates the production of Antibodies or against which Antibodies are Directed, or (b) any naturally occurring isoform or variants thereof. The whole protein, carbohydrate, compound or other composition as well as a portion of the whole is considered the same Antigen.", "samples": [{"hash": "bUQDjISpoCv", "uri": "/contracts/bUQDjISpoCv#antigen", "label": "Collaboration and Commercial License Agreement (Mersana Therapeutics, Inc.)", "score": 34.3497619629, "published": true}, {"hash": "bHKMWrplZc7", "uri": "/contracts/bHKMWrplZc7#antigen", "label": "Collaboration and Commercial License Agreement", "score": 31.3408622742, "published": true}, {"hash": "df0ANPdsiJb", "uri": "/contracts/df0ANPdsiJb#antigen", "label": "Collaboration and Commercial License Agreement (Mersana Therapeutics, Inc.)", "score": 28.414100647, "published": true}], "snippet_links": [{"key": "the-production", "type": "clause", "offset": [122, 136]}, {"key": "naturally-occurring", "type": "definition", "offset": [204, 223]}, {"key": "a-portion", "type": "definition", "offset": [327, 336]}], "hash": "c2f1f5630d6e13a991e3c5ad2dffdc5f", "id": 5}, {"size": 8, "snippet": "means any antigen, defined by its amino acid sequence, associated with a Pathogen, together with all Antigen Variants thereof.", "samples": [{"hash": "2DFEtAAqMa5", "uri": "/contracts/2DFEtAAqMa5#antigen", "label": "Licence Agreement (CureVac N.V.)", "score": 36.274471283, "published": true}, {"hash": "j02KvuFtwed", "uri": "/contracts/j02KvuFtwed#antigen", "label": "Covid Cla Third Amendment and Restatement Agreement (CureVac N.V.)", "score": 33.3203277588, "published": true}, {"hash": "fyU9yu51jLI", "uri": "/contracts/fyU9yu51jLI#antigen", "label": "Fourth Amendment and Restatement Agreement (CureVac N.V.)", "score": 33.3203277588, "published": true}], "snippet_links": [{"key": "amino-acid", "type": "clause", "offset": [34, 44]}, {"key": "associated-with", "type": "definition", "offset": [55, 70]}], "hash": "cce6fef3a05df6b1b705abc4e31de49a", "id": 6}, {"size": 8, "snippet": "means an HBV Antigen or an HIV Antigen, as the context requires.", "samples": [{"hash": "a2k40dq4tuE", "uri": "/contracts/a2k40dq4tuE#antigen", "label": "Research Collaboration and License Agreement (HOOKIPA Pharma Inc.)", "score": 33.1615333557, "published": true}, {"hash": "9fLy2LKWdcf", "uri": "/contracts/9fLy2LKWdcf#antigen", "label": "Research Collaboration and License Agreement (HOOKIPA Pharma Inc.)", "score": 32.2087593079, "published": true}, {"hash": "5ndDYSQGzbc", "uri": "/contracts/5ndDYSQGzbc#antigen", "label": "Research Collaboration and License Agreement (HOOKIPA Pharma Inc.)", "score": 31.2121829987, "published": true}], "snippet_links": [{"key": "hbv-antigen", "type": "definition", "offset": [9, 20]}, {"key": "hiv-antigen", "type": "definition", "offset": [27, 38]}, {"key": "the-context", "type": "clause", "offset": [43, 54]}], "hash": "e141920f831f346fe4cf264ef1b88658", "id": 7}, {"size": 7, "snippet": "means a molecule that causes an immune system response.", "samples": [{"hash": "itQLCfaw3fH", "uri": "/contracts/itQLCfaw3fH#antigen", "label": "License Agreement (Bellicum Pharmaceuticals, Inc)", "score": 31.8446273804, "published": true}, {"hash": "cPFYkMcqsDf", "uri": "/contracts/cPFYkMcqsDf#antigen", "label": "License Agreement", "score": 31.3408622742, "published": true}, {"hash": "jbjjGlVH3P5", "uri": "/contracts/jbjjGlVH3P5#antigen", "label": "License Agreement", "score": 30.4220199585, "published": true}], "snippet_links": [], "hash": "042564a90d3a1a026338ebaaac025c45", "id": 8}, {"size": 6, "snippet": "means [**].", "samples": [{"hash": "kB72ZcDtSi5", "uri": "/contracts/kB72ZcDtSi5#antigen", "label": "Collaboration and Commercial License Agreement (Mersana Therapeutics, Inc.)", "score": 34.1581115723, "published": true}, {"hash": "3anfNqVM1V1", "uri": "/contracts/3anfNqVM1V1#antigen", "label": "Research Collaboration and License Agreement (Mersana Therapeutics, Inc.)", "score": 33.3504447937, "published": true}, {"hash": "7rU2LXfMqv8", "uri": "https://ir.mersana.com/static-files/8aba2133-80cc-4575-b26b-9dc36afade02", "label": "ir.mersana.com", "score": 11.3545513153, "published": false}], "snippet_links": [], "hash": "d625c0c2cdb17b208fba7a69b82dd049", "id": 9}, {"size": 6, "snippet": "means the target molecule: .", "samples": [{"hash": "gKM04Dn49mD", "uri": "/contracts/gKM04Dn49mD#antigen", "label": "Master Agreement (Tanox Inc)", "score": 18.0, "published": true}, {"hash": "7aOLx8oo0cb", "uri": "/contracts/7aOLx8oo0cb#antigen", "label": "Master Agreement (Tanox Inc)", "score": 18.0, "published": true}, {"hash": "lxzATilvU9u", "uri": "http://investor.pdl.com/static-files/5d23d130-18f4-4c12-a4bd-710733b74a13", "label": "investor.pdl.com", "score": 9.1724843979, "published": false}], "snippet_links": [{"key": "the-target", "type": "clause", "offset": [6, 16]}], "hash": "7b129333486d2663ca740a414e7f7a21", "id": 10}], "next_curs": "ClQSTmoVc35sYXdpbnNpZGVyY29udHJhY3RzcjALEhpEZWZpbml0aW9uU25pcHBldEdyb3VwX3Y1NiIQYW50aWdlbiMwMDAwMDAwYQyiAQJlbhgAIAA=", "definition": {"title": "Antigen", "size": 278, "snippet": "means a substance recognized by the body as being foreign; it results in the production of specific antibodies directed against it.", "id": "antigen", "examples": ["However, Human Leukocyte <strong>Antigen</strong> testing is covered as indicated in the Summary of Medical Benefits.", "However, Human Leukocyte <strong>Antigen</strong> testing is covered as indicated in the Summary of Medical Benefits, subject to certain conditions.", "Human Leukocyte <strong>Antigen</strong> testing is covered as indicated in the Summary of Medical Benefits.", "<strong>Antigen</strong> excess will occur if there is not a slight antibody excess or <strong>antigen</strong>/antibody equivalency at the site of precipitation.", "<strong>Antigen</strong> excess in IFE is usually due to a very high level of immunoglobulin in the patient sample.", "Ministry of Health COVID-19 Guidance: Considerations for Rapid <strong>Antigen</strong> Screening.", "Used only for the purposes of the PASP (Provincial <strong>Antigen</strong> Screening Program).", "Appendix G sets forth a complete and accurate list of all agreements relating to the licensing, sublicensing or other granting of rights by Bluebird to any Person with respect to the Licensed IP and the Target <strong>Antigen</strong>, and Bluebird has provided complete and accurate copies of all such agreements to Celgene.", "Should an <strong>Antigen</strong> proposed by Merck be rejected by the Gatekeeper, the applicable nomination period for such <strong>Antigen</strong> shall be automatically extended by the time consumed by the unsuccessful nomination process.", "It is understood and agreed that Celldex shall not be obligated to assign to Medarex patent rights in any inventions that consist solely of the compositions of such Research <strong>Antigen</strong> itself."], "related": [["antibody", "Antibody", "Antibody"], ["receptor", "Receptor", "Receptor"], ["preceptor", "Preceptor", "Preceptor"], ["licensed-antibody", "Licensed Antibody", "Licensed Antibody"], ["opioid-antagonist", "Opioid antagonist", "Opioid antagonist"]], "related_snippets": [], "updated": "2026-02-28T06:15:34+00:00"}, "json": true, "cursor": ""}}